The annual J.P. Morgan Healthcare Conference seemed to be all anyone in the biopharmaceutical industry could talk about in the week preceding the meeting, being held Jan. 8 to 11 in San Francisco, and certainly was top of mind for companies announcing new venture capital financings, such as the mysterious Gossamer Bio Inc., which disclosed $100m in seed and Series A funding on Jan. 4.
Gossamer is keeping details about its pipeline close to the vest. However, Otello Stampacchia – managing director of the company's seed investor and Series A co-lead investor Omega Funds – referred to the San Diego, Calif
Omega acquired the asset against an undisclosed target from an unnamed European company, which unsuccessfully tested the compound in large indications. Stampacchia told Scrip that the asset was attractive to the investment fund, because of its potential in more targeted populations
